The T-42 (also known as the TG-V) was a Soviet super-heavy tank project of the interwar period. It was developed in 1932 by the OKB -5 design bureau at Bolshevik Plant no. 232 under the direction of a German engineer-designer Edward Grote [de; ru]. Development did not advance past the stage of construction drawings and scale models.

2024年10月16日 · The current European Stroke Organisation expedited recommendation on tenecteplase (TNK) for acute ischemic stroke (AIS) advocates that TNK 0.25 mg/kg can be used alternatively to alteplase (tissue plasminogen activator [TPA]) for AIS of <4.5 hours duration, based on a meta-analytical approach establishing noninferiority.

2023年5月23日 · 该研究评价了在中国卒中患者人群中，使用0.25 mg/kg TNK对比标准剂量rt-PA静脉溶栓的安全性和有效性，结果与国际多项研究一致。 另外，对于大血管闭塞且发病6 h内的卒中患者，使用TNK替代rt-PA静脉溶栓是否能获得更好的再灌注水平和血管再通率？

2025年3月4日 · Intra-Arterial Tenecteplase Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization (ANGEL-TNK): A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint Trial. In the past three years, growing evidence suggests that intra-arterial (IA) thrombolytics improve neurological outcomes in patients with large ...

替奈普酶（TNK）是一种从阿替普酶（rt-PA）衍生的基因工程药物。 其半衰期较长，可通过推注快速给药，与 rt-PA 相比具有后勤优势。 此外，TNK 对纤溶酶原激活剂抑制剂-1 失活的抵抗力增强，从而更有效地溶解富含血小板的凝块。

2024年11月12日 · The updated meta-analysis confirms similar safety between TNK 0.25 mg/kg and TPA, while showing that TNK is superior to TPA regarding excellent functional outcome and reduced disability at 3 months. These findings support transitioning to TNK in clinical practice.

2022年7月14日 · TNK was developed as a plasminogen activator with greater fibrin specificity and reduced clearance compared with alteplase. Besides above, advantages of TNK include ease of administration as a single-bolus and shorter time to initiate interfacility transfer following intravenous lytic administration.

2024年8月26日 · Tenecteplase (TNK) or its similar drug recombinant human tissue-type plasminogen activator were bioengineered with mutations at three genetic loci on the bases of the alteplase molecule.2 Based on its prolonged half-life and improved specificity for fibrinolysis compared with alteplase,3 TNK can be administered in a single bolus and does not ...

2024年1月6日 · Outcome data regarding the administration of tenecteplase (TNK) to acute ischemic stroke (AIS) patients presenting in the extended time window are limited. We aimed to assess the current evidence regarding the efficacy and safety of TNK at a dose of 0.25 mg/kg for AIS treatment in the extended time window.

2024年9月13日 · 研究结果显示，对于发病4.5小时静脉溶栓窗内的急性缺血性卒中患者，使用替奈普酶（tnk）在90天时的良好功能结局方面不劣于阿替普酶，且安全性相似。